The Results of a Three Year Analysis on Sarcoidosis Patients Registered in the Regis Electronic Registry


Introduction. Registries are necessary particularly for rare diseases. The REGIS registry was developed to improve scientific research in the field of interstitial lung diseases (ILDs).

Material and Method. We analysed 144 patients with interstitial lung diseases enrolled during a three year period, selected the sarcoidosis cases and analysed the data with Excel 2007 Software.

Results. A number of 26 sarcoidosis patients were included (18.06% out of the total), of which 46.15% were female, with an average age of 41.34±9.84 years; 23.08% were smokers. 88.46% pf patients had mediastinum pulmonary involvement: stage II in 17 patients, stage III in 5 patients and stage IV in one patient; only 3 patients had extra thoracic involvement. The medical investigations performed were: chest X-ray (96.15%), thoracic HRCT (96.15%) that identified hilar adenopathy (96%), nodules (68%), with peribronchovascular localization (44%); spirometry (96.15%) that revealed an average CV of 94.99±23.07% out of the predicted value, DLCO 78.41±19.39% out of the predicted value; bronchoalveolar lavage (38.46%); serum angiotensin-converting enzyme (73.08%) and pulmonary or lymph node biopsy (80.77%). The patients that needed treatment (46.15%) were administered oral corticosteroids (10 patients), acetylcysteine (1 patient) and pirfenidone (1 patient).

Conclusions. The number of patients enrolled is low as a result of the voluntary reporting, especially in severe cases and with access to all investigations needed for diagnosing.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Gliklich RE, Dreyer NA, Leavy MB. Rare Disease Registries [Internet]. Agency for Healthcare Research and Quality (US); 2014 [cited 2018 Mar 26]. Available from:

  • 2. Michael A. Nead, David G. Morris. Interstitial and Inflammatory Lung Diseases. In: Fishman's Pumonary Disease and Disorders Authors Alfred P Fishman, Jack A Elias, Robert M Senior, Jay A Fishman, Allan I Pack, Michael A Grippi. 2008. p. 11057, 1112.

  • 3. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004 Aug;91(Suppl 2):S310.

  • 4. Munakata M, Asakawa M, Hamma Y, Kawakami Y. [Present status of idiopathic interstitial pneumonia--from epidemiology to etiology]. Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Dec;32 Suppl:18792.

  • 5. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia. Acta Univ Palacki Olomuc Fac Med. 1994;137:4950.

  • 6. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002 Apr;57(4):33842.

  • 7. Xaubet A, Ancochea J, Morell F, Rodriguez-Arias JM, Villena V, Blanquer R, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2004 Mar;21(1):6470.

  • 8. Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009 Aug;103(8):11229.

  • 9. Ionita D. Sarcoidoza. În Ghid de diagnostic şi tratament al pneumopatiilor interstiţiale difuze Coordonatori: Strâmbu I., Tudorache V. Bucureşti: Editura Curtea Veche; 2015. 7683 p.

  • 10. Park JE, Kim YS, Kang MJ, Kim CJ, Han CH, Lee SM, et al. Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003-2015: A nationwide population-based study. Respir Med. 2018 Apr 3;

  • 11. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007 Nov 22;357(21):215365.


Journal + Issues